3305 results about "Ethyl phosphate" patented technology

Composition for pharmaceutical or cosmetic use, capable of forming a microemulsion, comprising at least: an active principle, a lipophilic phase consisting of a mixture of fatty acid esters and glycerides, a surfactant (SA), a cosurfactant (CoSA), a hydrophilic phase, characterized: in that the lipophilic phase consists of a mixture of C8 to C18 polyglycolized glycerides having a hydrophilic-lipophilic balance (HLB) of less than 16, this lipophilic phase representing from 30 to 75% of the total weight of the composition; in that the surfactant (SA) is chosen from the group comprising saturated C8-C10 olyglycolized glycerides and oleic esters of polyglycerol, this surfactant having an HLB of less than 16; in that the cosurfactant (CoSA) is chosen from the group comprising lauric esters of propylene glycol, oleic esters of polyglycerol and ethyl diglycol; in that the SA/CoSA ratio is between 0.5 and 6; and in that the hydrophilic phase of the final microemulsion is supplied after ingestion by the physiological fluid of the digestive milieu.

The present invention relates to large scale preparation of LNA phosphoramidites using a 2-cyanoethyl-N,N,N′,N′-tetra-substituted phosphoramidite and a nucleophilic activator, e.g. 2-cyanoethyl-N,N,N′,N′-tetraisopropylphosphoramidite and 4,5-dicyanoimidazole. The method is faster and more cost efficient that previously known methods.

There are disclosed a method for removing CO2 from a combustion exhaust gas which comprises the step of bringing the combustion exhaust gas under atmospheric pressure into contact with an aqueous solution of a hindered amine selected from the group consisting of 2-amino-2-methyl-1-propanol, 2-methylaminoethanol, 2-ethylaminoethanol and 2-piperidineethanol; and another method for removing carbon dioxide from a combustion exhaust gas which comprises the step of bringing the combustion exhaust gas under atmospheric pressure into contact with a mixed aqueous solution of 100 parts by weight of an amine compound (X) selected from the group consisting of 2-amino-2-methyl-1,3-propanediol, 2-amino-2-methyl-1-propanol, 2-amino-2-ethyl-1,3-propanediol, t-butyldiethanolamine and 2-amino-2-hydroxymethyl-1,3-propanediol; and 1-25 parts by weight of an amine compound (Y) selected from the group consisting of piperazine, piperidine, morpholine, glycine, 2-methylaminoethanol, 2-piperidineethanol and 2-ethylaminoethanol.

The provides compounds for the treatment of sickle-cell disease. In particular, the invention provides 5-membered heterocyclic anti-sickling agents that are highly effective and non-toxic, and methods for their use. The compounds include analogues and derivatives of naturally occurring occurring 5-hydroxymethyl-2-furfuraldehyde, 5-Ethyl-2-furfuraldehyde, 5-Methyl-2-furfuraldehyde, and 2-furfuraldehyde, and prodrug forms of the compound.

Cosmetic compositions containing a micronized metal oxide along with a 4-substituted resorcinol derivatives of the general formula I exhibit improved storage stability:

• • where each R₁ and R₂, independently, represents a hydrogen atom, —CO—R (acyl group), —COO—R, CONHR; where R represents saturated or unsaturated, linear, branched or cyclic C₁-C₁₈ hydrocarbon groups; and
  • R₃ represents (1) an alkyl group, having from 1 to 18 carbon atoms, preferably having from 2 to 12 carbon atoms, with or without substitution of one or more hydrogen atoms of a linear alkyl group with a methyl or ethyl group; e.g., R₃ constitutes linear or branched chain alkyls, or (2) a group of the general formula formula (II)
  • Where X is preferably H, n is 0 to 3 and the dashed lines represents an optional double bond.

Use is made, for selectively hydrogenating the olefinic double bonds of block copolymers, at least one block of which comprises olefinic double bonds, using a catalyst based on a metal from Group VIII in a medium comprising an organic solvent for the copolymer and an ionic liquid as solvent for the catalyst, of a water-immiscible ionic liquid, preferably an ionic liquid for which the anion is the hexafluorophosphate anion and the cation is the 1-butyl-3-methylimidazolium (bmim⁺) or 1-ethyl-3-methylimidazolium (emim⁺) cation.

Applied to poly(styrene)-b-poly(butadiene)-b-poly(methyl methacrylate) block copolymers, the poly(butadiene) block of which predominantly possesses a 1,4-microstructure, this process results in copolymers for which the degree of hydrogenation is at least equal to 50% and which exhibit a melting point of greater than 30 °C.

A heavy oil cleaning composition comprising: a) a blend of dibasic esters comprising dialkyl methylglutarate and at least one of a dialkyl adipate or dialkyl ethylsuccinate; b) at least one terpene; and c) at least one surfactant. Also described are methods for delivering a solvent at reduced concentration comprising the steps of: a) obtaining a terpene-based solvent; and b) mixing the terpene-based solvent with a carrier fluid (the carrier fluid comprising a microemulsion of i) a blend of dibasic esters selected from the group consisting of dialkyl methylglutarate, dialkyl adipate, dialkyl ethylsuccinate, dialkyl succinate, dialkyl glutarate and any combination thereof, ii) at least one surfactant selected from the group consisting of a terpene alkoxylate, an alcohol alkoxylate and any combination thereof; and iii) water) in order to obtain a mixture to clean heavy oils.

The invention provides a preparation method of brivaracetam. The preparation method of brivaracetam comprises the following steps of in an alkaline reagent, reacting malonate ester and (R)-epichlorohydrin to obtain lactone (II), reacting the lactone (II) and an ethyl metal-based reagent to obtain an intermediate (III), removing carboxylase to obtain (R)-4-propyl-dihydrofuran-2-ketone (IV), performing ring-opening reaction under the action of a halogenated ring-opening reagent to obtain (R)-3-halogenarated methyl hexanoate or (R)-3- halogenarated methyl hexyl acetate (V), and reacting with (S)-2-aminobutanamide or an acceptable salt, so as to obtain the brivaracetam. The preparation method has the advantages that the high-purity brivaracetam (HPLC (high performance liquid chromatography: greater than 96%) and stereo rotary brivaracetam (chirality HPLC: greater than 98%) can be directly prepared; the silicagel column separation and purification or the chirality preparation column separation and purification is not used, so that the complicated separation and purification step is not performed, the cost is saved, and the preparation method is more suitable for industrial production.

The invention relates to a functional fiber and its manufacturing method, where the functional fiber has a skin-core structure, the weight ratio of skin to core 3/7 - 7/3; and the formula of the skin materials in weight percent comprises: skin polymer 91.6-97.6%, far infrared powder 2-8%, and coupling agent 0.1-0.4%; the skin polymer is one of PTT, PBT, PA-6, PET and PP with fusion index of 25-50; the coupling agent is one of gama-shink glycerol oxy propyl trimethoxy silane, gama-methyl propylene acyl oxy trimethoxy silane, N-beta-(amido ethyl)-gama amido propyl trimethoxy silane, and gama-amido propyl triethoxy silane; and the formula of the core-layer materials in weight percent comprises: core-layer polymer 88-99%, and flavor 1-12%; wherein the core-layer polymer is one of PE, PP and PET with melting point of 150-200 deg.C. The fiber of the invention has far infrared emissivity of 81-86%, very strong spicery and is a synthetic health functional fiber.

Hair treatment compositions in the form of pump sprays and pump foams that are free from propellant gases comprise at least one cationic and at least one anionic polymer having methacrylic and ethyl units.

The invention belongs to the field of medicine, and in particular relates to a medical application of 2-([1,1'-biphenyl]-4-yl)-2-oxoethyl 4-((3-chloro-4-methylphenyl) amino)-4-oxobutanoate in a selective histone lysine-specific demethylase 1 (LSD1) inhibitor, especially the application in anti-tumor medicaments. Pharmacodynamic tests indicate that the 2-([1,1'-biphenyl]-4-yl)-2-oxoethyl 4-((3-chloro-4-methylphenyl) amino)-4-oxobutanoate has a remarkable LSD1 inhibiting effect, and has selectivity to homologous proteins MAO-A (monoamine oxidase-A) and MAO-B.

Cosmetic compositions containing organic sunscreens along with a 4-substituted resorcinol derivatives of general formula I exhibit improved storage stability and oxidative stability:

where each R₁ and R₂, independently, represents a hydrogen atom, —CO—R (acyl group), —COO—R CONHR; where R represents saturated or unsaturated, linear, branched or cyclic C₁-C₁₈ hydrocarbon groups; and

R₃ represents (1) an alkyl group, having from 1 to 18 carbon atoms, preferably having from 2 to 12 carbon atoms, with or without substitution of one or more hydrogen atoms of a linear alkyl group with a methyl or ethyl group; e.g., R₃ constitutes linear or branched chain alkyls, or (2) a group of the general formula formula (II)

Where X is preferably H, n is 0 to 3 and the dashed lines represents an optional double bond.

The invention relates to administration of an anti-CTLA4 antibody, particularly human antibodies to human CTLA4, such as those having amino acid sequences of antibodies 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, ticilimumab (also referred to as 11.2.1 or CP-675,206), 11.6.1, 11.7.1, 12.3.1.1, 12.9.1.1, and ipilimumab (also referred to as 10D1 or MDX-010), in combination with an indolinone receptor tyrosine kinase inhibitor (RTKI), e.g., N-[2-diethylamino]ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (compound 1), N-[2-(ethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (compound 2), and 5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (compound 3), for treatment of cancer. The invention relates to administering a combination of an anti-CTLA4 antibody and an indolinone RTKI such as, inter alia, compound 1. The invention relates to neoadjuvant, adjuvant, first-line, second-line, and third-line therapy of cancer, whether localized or metastasized, and at any point(s) along the disease continuum (e.g., at any stage of the cancer).

Disclosed is a herbicidal mixture comprising (a) at least one herbicide compound selected from the pyrimidines of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof:

wherein

• • R¹ is cyclopropyl, 4-Br-phenyl or 4-Cl-phenyl;
  • X is Cl or Br;
  • R² is H, C₁-C₁₄ alkyl, C₂-C₁₄ alkoxyalkyl, C₃-C₁₄ alkoxyalkoxyalkyl, C₂-C₁₄ hydroxyalkyl or benzyl; and
  • (b) at least one additional herbicide or herbicide safener compound selected from the group consisting of (b1) ACCase inhibitors, (b2) AHAS inhibitors, (b3) photosystem II inhibitors, (b4) photosystem I electron diverters, (b5) PPO inhibitors, (b6) EPSP synthase inhibitors, (b7) GS inhibitors, (b8) VLCFA inhibitors, (b9) auxin mimics, (b10) auxin transport inhibitors, (b11) other herbicides selected from the group consisting of flamprop-M-methyl, flamprop-M-isopropyl, difenzoquat, DSMA, MSMA, bromobutide, flurenol, cinmethylin, cumyluron, dazomet, dymron, methyldymron, etobenzanid, fosamine-ammonium, isoxaflutole, asulam, clomazone, mesotrione, metam, oxaziclomefone, oleic acid, pelargonic acid and pyributicarb, (b12) herbicide safeners selected from the group consisting of benoxacor, 1-bromo-4-[(chloromethyl)sulfonyl]benzene, cloquintocet-mexyl, cyometrinil, dichlormid, 2-(dichloromethyl)-2-methyl-1,3-dioxolane, fenchlorazole-ethyl, fenclorim, flurazole, fluxofenim, furilazole, isoxadifen-ethyl, mefenpyr-diethyl, methoxyphenone, naphthalic anhydride and oxabetrinil, and their salts. Also disclosed is a method for controlling the growth of undesired vegetation comprising contacting the vegetation or its environment with a herbicidally effective amount of a mixture of the invention (e.g., as a composition described herein).

The present invention is a formable dental treatment tray utilizing poly(2-ethyl-2-oxazoline) and a gelatinous active. Blending of the active is accomplished by mixing the Poly(2-ethyl-2-oxazoline) with an active ingredient, such as a peroxide like hydrogen peroxide, carbamide peroxide, sodium perborate, or sodium percarbonate, usually also with water or an appropriate organic solvent. Peroxide concentrations in these new gels can reach a 30% concentration of hydrogen peroxide while maintaining a shelf life of six months at room temperature without developing peroxide decomposition. The gels are applied to an appropriate backing and dried to a gelatinous state. In use, the active is hydrated and regains adhesiveness. Then the tray is pressed and formed around a user's dental arch to form the customizable tray. Multiple active ingredients may be used, with or without peroxide, for accomplishing desired treatment regimens.

Polyalkylene carbonate resins are stabilized against thermal and hydrolytic decomposition by the addition of a cyclic amine eliminating the need for complex chemical or other purifying techniques. Cyclic amines such as imidazole and substituted imidazoles (specifically 2-ethyl 4-methyl imidazole) were found to be effective at 5-30%, preferably 10-30%. Processes for producing stable flux containing coatings for the aluminum brazing industry are detailed. The modified polyalkylene carbonate resins have better adhesive properties than the unmodified resins while maintaining their low ash, clean burning characteristics.

Provided herein are optically active compounds of the formulae (ii); and (III) and pharmaceutical compositions thereof. Also provided herein are processes of making these compounds and resolving the racemic mixture or the enrichment of same with in one of its enantiomers to provide (R)- and (S)-1-(3-(3-N,N-dimethylaminocarbonyl)phenoxyl-4-nitrophenyl)-1-ethyl-N,N'-bis(ethylene)phosphoramidate, andmethods of treating cancer comprising administering such compounds.

A crystal form of folic acid antagonistic N-(4-(2-(2-amino-4,7-methyl-4-oxo-1H-pyrrolo(2,3-d)pyrimidine-5-radical)ethyl)benzoyl)-L-glutamic acid disodium salt and its production are disclosed.

The invention discloses a preparation method of polydopamine modified alginic acid microspheres, which comprises the following steps of: under the protection of nitrogen, grafting dopamine to alginic acid by use of N-hydroxysuccinimide and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride; polymerizing the synthesized dopamine modified alginic acid under the slight alkaline condition to obtain a polydopamine modified alginic acid solution; dropwise adding the polydopamine modified alginic acid solution into a CaCl2 solution by a syringe; and aging to obtain polydopamine modified alginic acid microspheres. The method disclosed by the invention is simple in process, and the prepared modified alginic acid microspheres have higher swelling resistance and good mechanical properties.

The present invention relates to the preparation of Timisatan as one active component for antihypertensive medicine. The carboxylic ester derivative is first obtained through the nucleophilic substitution reaction between some intermediate and 4'-bromomethyl biphenyly-2-carboxylic ester, and then hydrolyzed to eliminnate protection radical and to obtain the destination product. In the technological process of the present invention, methyl radical and ethyl radical are used as protecting radical, and this facilitates and stabilizes the preparation of 4'-bromomethyl biphenylyl-2-methyl carboxylic ester and 4'-bromomethyl biphenylyl-2-ethyl carboxylic ester, and results in easy to control reaction with the intermediate, less impurity, easy elimination of protecting radical and high product yield and quality.

This invention is drawn to a process for producing and recovering one or more high-purity xylene isomers from a feed stream having a substantial content of C₉ and heavier hydrocarbons. The feed stream is processed to de-ethylate heavy aromatics, fractionated and passed to a circuit comprising C₈-aromatic isomer recovery and isomerization to recover the high-purity xylene isomer with lowered energy costs.